MRI FDG PET Imaging Cervix
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01899404|
Recruitment Status : Active, not recruiting
First Posted : July 15, 2013
Last Update Posted : December 4, 2017
The standard treatment for cervix cancer at Princess Margaret Hospital is external radiation with chemotherapy followed by internal radiation, called brachytherapy. Currently, brachytherapy treatment is planned on a type of Magnetic Resonance Imaging (MRI) called T2-weighted (T2W) MRI.
The main purpose of this study is to determine whether the following imaging tests can visualize the tumor better for planning the brachytherapy treatment:
- special types of MRI called diffusion weighted MRI (DWI) and dynamic-contrast enhanced MRI (DCE-MRI); and
- an x-ray test called positron emission test (PET) performed with a sugar dye called FDG. MRI-guided brachytherapy is resource-intensive and not widely available.
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer Squamous Cell||Biological: 18-FDG PET/CT, DWI, DCE-MRI||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer|
|Actual Study Start Date :||October 3, 2012|
|Actual Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||October 2018|
|Experimental: 18-FDG PET/CT, DWI, DCE-MRI||
Biological: 18-FDG PET/CT, DWI, DCE-MRI
All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
- Target delineation in brachytherapy using standard T2-weighted MRI versus DCE-MRI, DWI and FDG-PET/CT imaging: gross tumor volume and high-risk clinical target volume in patients with cervical cancer [ Time Frame: 2 years ]
- Target delineation using standard MRI acquired during the last week of EBRT fused to planning CT versus full MRI-guided brachytherapy. [ Time Frame: 2 years ]This objective will evaluate the potential for translation of this technique to centres with limited MRI access.
- Follow-up imaging (MRI and 18FDG PET) versus the imaging done at the time of brachytherapy [ Time Frame: 2 years ]
- Imaging techniques for visualizing the brachytherapy applicator. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01899404
|University Health Network, The Princess Margaret|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Kathy Han, MD||University Health Network, The Princess Margaret|